Bone Biologics (OTC:BBLG) Trading Down 19.7% – What’s Next?

Bone Biologics Co. (OTC:BBLG)’s stock price was down 19.7% during trading on Tuesday . The stock traded as low as $1.20 and last traded at $1.39. Approximately 722,882 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 1,613,719 shares. The stock had previously closed at $1.73.

Bone Biologics Stock Performance

The stock has a market cap of $1.53 million, a PE ratio of -0.03 and a beta of 0.40. The business has a 50 day moving average price of $1.67 and a two-hundred day moving average price of $1.61.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.